Sibylla Biotech S.p.A. articles

A new structural target for drug development against COVID-19 has been unveiled today by Sibylla Biotech in collaboration with the Italian National Institute of Nuclear Physics (INFN), the University of Trento and University of Perugia.The breakthrough drug discovery strategy pioneered by Sibylla in this study would not only promise to reduce the risk of drug resistance and harmful side effects, but it also opens new avenues for the therapy of other viral and non-viral diseases.The results ha

And its first validation is now published on Nature Communications Biology!

Spagnolli, G., Massignan, T., Astolfi, A. et l. Pharmacological inactivation of the prion protein by targeting a folding intermediate. Commun Biol 4, 62 2021).

Recent computational advancements in the simulation of biochemical processes allow investigating the mechanisms involved in protein regulation with realistic physics-based models, at an atomistic level of resolution. The